Showing results (71-80 of 106) with videos related to
Sort By:
Pageof 11
Journal of Alzheimer'S Disease : JAD|October 31, 2022
COVID-19 as a Risk Factor for Alzheimer's DiseaseMahdieh Golzari-Sorkheh, Donald F Weaver, Mark A ReedFEBS Letters|March 1, 2005
The "promiscuous drug concept" with applications to Alzheimer's diseaseVanessa C Stephenson, R Andrew Heyding, Donald F WeaverACS Chemical Neuroscience|January 21, 2022
Anti-Inflammatory Anthranilate Analogue Enhances Autophagy through mTOR and Promotes ER-Turnover through TEX264 during Alzheimer-Associated NeuroinflammationZhiyu Wang, Junbo Huang, Seung-Pil Yang, et al.The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques|April 14, 2005
A spontaneous recurrent seizure bioassay for anti-epileptogenic moleculesAngela P Lyon, Dan Wainman, Sandra Marone, et al.Pain Research & Management|January 9, 2003
Patients' attitudes and prior treatments in neuropathic pain: a pilot studyIan Gilron, Joan Bailey, Donald F Weaver, et al.Journal of Molecular Modeling|August 24, 2004
Molecular modeling of the von Willebrand factor A2 Domain and the effects of associated type 2A von Willebrand disease mutationsJeffrey J Sutherland, Lee A O'Brien, David Lillicrap, et al.Physical Chemistry Chemical Physics : PCCP|November 27, 2019
Understanding the effect of nanoconfinement on the structure of water hydrogen bond networksMyong In Oh, Mayuri Gupta, Chang In Oh, et al.Journal of Medicinal Chemistry|October 12, 2019
The Blood-Brain Barrier (BBB) ScoreMayuri Gupta, Hyeok Jun Lee, Christopher J Barden, et al.The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques|March 30, 2023
Alzheimer's Disease and COVID-19 Pathogenic Overlap: Implications for Drug RepurposingMahdieh Golzari-Sorkheh, Imindu Liyanage, Mark A Reed, et al.Journal of Medicinal Chemistry|February 11, 2021
Furazans in Medicinal ChemistryRoss S Mancini, Christopher J Barden, Donald F Weaver, et al.Pageof 11